Akcea Therapeutics and Ionis Pharmaceutical Launch Waylivra (volanesorsen) for Familial Chylomicronemia Syndrome in EU
Shots:
- The EC’s MAA is based on the P-III APPROACH study results assessing of Waylivra vs PBO in 66 patients with FCS and the ongoing APPROACH OLE study and is supported by P-III COMPASS study results
- The P-III APPROACH study resulted in the reduction in triglyceride levels (77% vs 18%) with a reduction in apoC-III by 84% and were published in the August 8th issue of the NEJM entitled “Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.”
- Waylivra is the only therapy and is based on Ionis’ antisense technology act by reducing the production of apoC-III- thus regulating plasma triglycerides. Akcea is working to confirm a path forward for WAYLIVRA in the US and Canada
Click here to read full press release/ article | Ref: Akcea Therapeutics | Image: Pharma Journalist
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com